home.social

#drugpricing — Public Fediverse posts

Live and recent posts from across the Fediverse tagged #drugpricing, aggregated by home.social.

fetched live
  1. Flagship, Pentagon, AstraZeneca, GSK: Readout Newsletter

    Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected…
    #EuropeSays #Britain #Europe #EU #GSK #biotech #Biotechnology #drugdevelopment #Drugprices #Drugpricing #Pharmaceuticals #policy #research
    europesays.com/britain/130090/

  2. Florida Sues Eli Lilly, Sanofi, CVS in Insulin Antitrust Action

    The largest makers of insulin and GLP-1s, as well as pharmacy benefit manager giants and rebate companies, were…
    #France #FR #Europe #EU #Sanofi #drugpricing #pharmacybenefitmanagement #pharmacycare #stateantitrustlaw
    europesays.com/france/82884/

  3. As the US investigates German drug prices, here’s why Europe should care – POLITICO

    Germany was the first EU country to come under specific pressure to raise drug prices, after the U.S.…
    #Europe #EU #cars #Drugpricing #EuropeanUnion #Germany #Medicines #patientaccess #Pharma #ResearchandDevelopment #Tariffs #UnitedKingdom #UnitedStates
    europesays.com/europe/144378/

  4. Florida Sues Eli Lilly, Sanofi, CVS in Insulin Antitrust Action

    The largest makers of insulin and GLP-1s, as well as pharmacy benefit manager giants and rebate companies, were…
    #France #FR #Europe #EU #Sanofi #drugpricing #pharmacybenefitmanagement #pharmacycare #stateantitrustlaw
    europesays.com/france/82872/

  5. Annika Kim Constantino reports that new drug pricing moves may reshape costs for millions of patients. Under a "most favored nation" policy, several pharmaceutical companies are entering voluntary deals to align U.S. medication prices with lower international rates in exchange for certain Medicare exemptions. While the specific impact on out-of-pocket costs is still unfolding, these agreements highlight significant political and industry pressure regarding healthcare affordability. Read more about how these shifts affect patients and industry strategy here: cnbc.com/2026/08/31/trump-drug #DrugPricing #HealthcareReform

  6. Annika Kim Constantino reports that new drug pricing moves may reshape costs for millions of patients. Under a "most favored nation" policy, several pharmaceutical companies are entering voluntary deals to align U.S. medication prices with lower international rates in exchange for certain Medicare exemptions. While the specific impact on out-of-pocket costs is still unfolding, these agreements highlight significant political and industry pressure regarding healthcare affordability. Read more about how these shifts affect patients and industry strategy here: cnbc.com/2026/08/31/trump-drug #DrugPricing #HealthcareReform

  7. Iowa audit says PBMs turned accounting moves into millions in profit

    Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He…
    #NewsBeep #News #US #USA #UnitedStates #UnitedStatesOfAmerica #Healthcare #drugpricing #Health #Medicaid #Pharmaceuticals #STAT+
    newsbeep.com/us/775097/

  8. Iowa audit says PBMs turned accounting moves into millions in profit

    Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He…
    #NewsBeep #News #US #USA #UnitedStates #UnitedStatesOfAmerica #Healthcare #drugpricing #Health #Medicaid #Pharmaceuticals #STAT+
    newsbeep.com/us/775097/

  9. FDA approves Colorado’s plan to import cheaper drugs from Canada

    Lizzy leads STAT’s coverage of the FDA. Her stories explore the relationship between politics and science at the…
    #Canada #biotechnology #drugpricing #Pharmaceuticals #policy #STAT+
    europesays.com/canada/89854/

  10. FDA approves Colorado’s plan to import cheaper drugs from Canada

    Lizzy leads STAT’s coverage of the FDA. Her stories explore the relationship between politics and science at the…
    #Canada #biotechnology #drugpricing #Pharmaceuticals #policy #STAT+
    europesays.com/canada/89438/

  11. Capricor Therapeutics accuses Nippon Shinyaku of slow-walking Duchenne drug

    Capricor Therapeutics accused Nippon Shinyaku and its U.S. subsidiary of failing to follow through on marketing plans for…
    #NewsBeep #News #Healthcare #AU #Australia #Biotechnology #Drugpricing #Health #Pharmaceuticals #STAT+
    newsbeep.com/au/660234/

  12. Capricor Therapeutics accuses Nippon Shinyaku of slow-walking Duchenne drug

    Capricor Therapeutics accused Nippon Shinyaku and its U.S. subsidiary of failing to follow through on marketing plans for…
    #NewsBeep #News #Healthcare #AU #Australia #Biotechnology #Drugpricing #Health #Pharmaceuticals #STAT+
    newsbeep.com/au/660234/

  13. Capricor Therapeutics accuses Nippon Shinyaku of slow-walking Duchenne drug

    Capricor Therapeutics accused Nippon Shinyaku and its U.S. subsidiary of failing to follow through on marketing plans for…
    #NewsBeep #News #Healthcare #Biotechnology #Drugpricing #Health #healthcare #Pharmaceuticals #STAT+ #UK #UnitedKingdom
    newsbeep.com/uk/574926/

  14. Drug Giant Eli Lilly Shuns Subsidised Medication Listing, Citing Unfair Price

    Eli Lilly refused to list its diabetes drug Mounjaro on Australia's PBS because the government's offered price was too low. This affects 450,000 Australians with Type 2 diabetes.

    #EliLilly, #Mounjaro, #DiabetesAustralia, #PBS, #DrugPricing

    newsletter.tf/eli-lilly-refuse

  15. Eli Lilly's decision means Mounjaro won't be subsidised on Australia's PBS. This affects around 450,000 people with Type 2 diabetes who might not get cheaper access to the drug.

    #EliLilly, #Mounjaro, #DiabetesAustralia, #PBS, #DrugPricing
    newsletter.tf/eli-lilly-refuse

  16. Toddler Captures Oval Office Spotlight Amid Policy Discussions

    A 2-year-old boy's hearing was restored by a Regeneron drug, overshadowing talks on drug costs in the Oval Office on April 23, 2026.

    #HearingRestoration, #DrugPricing, #OvalOffice, #Regeneron, #TravisSmith

    newsletter.tf/toddler-hearing-

  17. Vas Narasimhan, Novartis CEO, warns of serious long-term consequences from President Trump's most favored nation drug pricing policy. The real impact on drugmakers and patients is expected within 18 months as U.S. prices link to lower foreign rates. This policy is set to stay, urging nations to rethink drug pricing strategies. Learn more about its implications. cnbc.com/2026/04/28/novartis-c #DrugPricing #Novartis #HealthcarePolicy

  18. Annika Kim Constantino reports: A historic agreement slashes drug prices! Regeneron will offer its FDA-approved hearing-loss gene therapy, Otarmeni, free to eligible U.S. patients. This move, made with President Trump, is a significant step for families needing alternatives to cochlear implants. Learn more about this monumental healthcare development.
    cnbc.com/2026/04/23/regeneron- #DrugPricing #Healthcare #GeneTherapy

  19. How a 340B successor might arise from the drug price negotiations

    The 340B drug discount program requires manufacturers to sell drugs to safety-net hospitals at deep discounts, so they…
    #NewsBeep #News #US #USA #UnitedStates #UnitedStatesOfAmerica #Medication #340B #drugpricing #Health #hospitals #Medicare
    newsbeep.com/us/533072/

  20. 340B Drug Pricing Program Under Scrutiny: Examining Program Goals and Real-World Effects

    The 340B program helps hospitals get cheaper drugs for poor patients. Learn how it works and why it's being discussed.

    #340BProgram, #DrugPricing, #HealthcareCosts, #PatientAccess, #HospitalSavings

    newsletter.tf/340b-drug-progra

  21. 340B Drug Pricing Program Under Scrutiny: Examining Program Goals and Real-World Effects

    The 340B program helps hospitals get cheaper drugs for poor patients. Learn how it works and why it's being discussed.

    #340BProgram, #DrugPricing, #HealthcareCosts, #PatientAccess, #HospitalSavings

    newsletter.tf/340b-drug-progra

  22. Critics Warn TrumpRx Will Further Enrich Big Pharma, Not Reduce Drug Prices

    Trump’s son is on the board of a prescription drug platform that may benefit from the direct-to-patient medicine sales.

    murica.website/2026/02/critics

  23. Critics Warn TrumpRx Will Further Enrich Big Pharma, Not Reduce Drug Prices

    Trump’s son is on the board of a prescription drug platform that may benefit from the direct-to-patient medicine sales.

    murica.website/2026/02/critics

  24. Critics Warn TrumpRx Will Further Enrich Big Pharma, Not Reduce Drug Prices

    Trump’s son is on the board of a prescription drug platform that may benefit from the direct-to-patient medicine sales.

    murica.website/2026/02/critics

  25. AOC vs CVS The Hearing That Exposed America’s Healthcare Racket

    AOC dismantles CVS Health’s CEO, exposing how corporate consolidation drives up costs, traps patients, and turns healthcare into a profit extraction machine.

    #AlexandriaOcasioCortez #corporateConsolidation #CVSHealth #DrugPricing #FTC #healthcareMonopoly #healthcareReform #MedicareForAll #pharmacyBenefitManagers wp.me/p1OjMZ-oE8
  26. As Trump Touts 9 New Prescription Drug Deals, Many Call for Systemic Reform

    The ongoing battle over Affordable Care Act subsidies has renewed calls for Medicare for All.

    murica.website/2025/12/as-trum

  27. As Trump Touts 9 New Prescription Drug Deals, Many Call for Systemic Reform

    The ongoing battle over Affordable Care Act subsidies has renewed calls for Medicare for All.

    murica.website/2025/12/as-trum

  28. As Trump Touts 9 New Prescription Drug Deals, Many Call for Systemic Reform

    The ongoing battle over Affordable Care Act subsidies has renewed calls for Medicare for All.

    murica.website/2025/12/as-trum

  29. Big Pharma Is Making Mexico Sick. Medicine and Supply Shortages Are Rampant.

    Mexico manufactures medical devices and medicines, but the majority are exported, leaving residents facing shortages.

    murica.website/2025/12/big-pha

  30. Big Pharma Is Making Mexico Sick. Medicine and Supply Shortages Are Rampant.

    Mexico manufactures medical devices and medicines, but the majority are exported, leaving residents facing shortages.

    murica.website/2025/12/big-pha

  31. Big Pharma Is Making Mexico Sick. Medicine and Supply Shortages Are Rampant.

    Mexico manufactures medical devices and medicines, but the majority are exported, leaving residents facing shortages.

    murica.website/2025/12/big-pha

  32. bbc.com/news/articles/cn0k520v

    A bad deal for the UK, as drug prices will be forced up.

    Pharmaceutical companies hate the bargaining power that the NHS enjoys because of its centralized purchasing system and will be delighted to see the UK government buckle under the US attack.

    The zero tariff agreement - even if the the Trump administration keeps its side of the bargain - will benefit corporations rather than patients.

    A bad day for the National Health Service and for the UK as a whole. A bad day for other countries too, as the Trump administration will certainly take this as a sign that bullying works when it comes to drug pricing.🙁

    ##UKPolitics #UKTrade ##DrugPricing #NHS #NationalHealthService #USUKRelations

  33. bbc.com/news/articles/cn0k520v

    A bad deal for the UK, as drug prices will be forced up.

    Pharmaceutical companies hate the bargaining power that the NHS enjoys because of its centralized purchasing system and will be delighted to see the UK government buckle under the US attack.

    The zero tariff agreement - even if the the Trump administration keeps its side of the bargain - will benefit corporations rather than patients.

    A bad day for the National Health Service and for the UK as a whole. A bad day for other countries too, as the Trump administration will certainly take this as a sign that bullying works when it comes to drug pricing.🙁

    ##UKPolitics #UKTrade ##DrugPricing #NHS #NationalHealthService #USUKRelations

  34. bbc.com/news/articles/cn0k520v

    A bad deal for the UK, as drug prices will be forced up.

    Pharmaceutical companies hate the bargaining power that the NHS enjoys because of its centralized purchasing system and will be delighted to see the UK government buckle under the US attack.

    The zero tariff agreement - even if the the Trump administration keeps its side of the bargain - will benefit corporations rather than patients.

    A bad day for the National Health Service and for the UK as a whole. A bad day for other countries too, as the Trump administration will certainly take this as a sign that bullying works when it comes to drug pricing.🙁

    ##UKPolitics #UKTrade ##DrugPricing #NHS #NationalHealthService #USUKRelations